<DOC>
	<DOCNO>NCT03072407</DOCNO>
	<brief_summary>This phase 1 , randomize , double-blind , placebo-controlled , sequential parallel group , MAD study evaluate safety , tolerability , pharmacokinetics pharmacodynamics four once-weekly subcutaneous dos PB-119 subject T2DM .</brief_summary>
	<brief_title>MAD Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics PB-119 Subjects With T2DM</brief_title>
	<detailed_description>Dose level 25 µg , 50 µg , 100 µg 200 µg dose regimen weekly 4 consecutive week evaluate</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Patients T2DM diagnose least 3 month prior screen take treatment make lifestyle modification ( i.e. , diet exercise ) least 4 week take metformin ( change treatment include dose past 2 month ) . 2 . In good general health determine investigator screen evaluation 3 . Male and/or female subject age 18 70 year , inclusive ; 4 . Are capable give informed consent comply study procedure ; 5 . Body Mass Index ( BMI ) approximately 22 40 kg/m2 ; 6 . Fasting Cpeptide test result must &gt; 0.4 nmol/L ; 7 . HbA1c ≥6.5 % ≤12 % ; 8 . Female subject must negative urine pregnancy test result prior enrollment . 9 . Nonsmoker , 10 . Willing able adhere study restriction confine clinical research center . 1 . Subjects personal family history medullary thyroid carcinoma ( MTC ) subject Multiple Endocrine Neoplasia syndrome type 2 ( MEN 2 ) ; 2 . Screening fast blood glucose ≤100 ≥270 mg/dL 3 . Type 1 diabetes mellitus , latent autoimmune diabetes adult ; diabetic neuropathy , retinopathy nephropathy ; 4 . Previous treatment approve investigational GLP1 mimetic ; 5 . Patients treat investigational drug within 6 week screen ; 6 . Subjects pancreatitis ; 7 . Clinically significant gastrointestinal disorder 8 . History symptom clinically significant cardiovascular disease , particularly coronary artery disease , arrhythmia , atrial tachycardia , 9 . Uncontrolled hypertension screening ; 10 . History clinically significant central nervous system disease include : transient ischemic attack , stroke , seizure disorder , depression , 11 . History liver disease 12 . History clinically significant renal disease 13 . Uncontrolled severe dyslipidemia ; 14 . Positive blood screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ; 15 . A hospital admission major surgery within 30 day prior screen ; 16 . A history prescription drug abuse , illicit drug use within 6 month prior screen ; 17 . A history alcohol abuse accord medical history within 6 month prior screen ; 18 . A positive screen alcohol , drug abuse ; 19 . An unwillingness inability comply food beverage restriction study participation ; 20 . Use prescription overthecounter ( OTC ) medication , herbal An 21 . Unwillingness male participant use appropriate contraceptive measure engage sexual intercourse female partner childbearing potential . Appropriate measure include use condom spermicide , female partner , use intrauterine device ( IUD ) , diaphragm spermicide , oral contraceptive , injectable progesterone , progesterone subdermal implant , tubal ligation . Sexual intercourse pregnant lactate woman prohibit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>